<>
According to research published by the team, the new approach creates a scalable supply of off-the-shelf immune cells that can be mass-produced, frozen, and deployed across multiple patients.
Bypassing Patient-Specific Bottlenecks
Traditional chimeric antigen receptor (CAR) T-cell therapies require extracting a patient’s own immune cells, modifying them in a laboratory, and reinfusing them. This custom process often takes several weeks and costs hundreds of thousands of dollars. By utilizing umbilical cord blood—known as a rich source of programmable, pluripotent stem cells—researchers aim to bypass individual manufacturing bottlenecks. Co-senior author Charlie Li stated that the team can generate trillions of therapeutic cells from a small quantity of cord blood stem cells in roughly six weeks, yielding thousands of potential treatment doses.
Targeting NY-ESO-1 and Mutation Risks
The technology falls under the T-cell receptor (TCR) therapy class. Researchers introduce a gene into the stem cells that programs them to produce receptors capable of recognizing NY-ESO-1, a protein expressed across several types of cancer. As these stem cells divide and mature into functional T cells, nearly all daughter cells inherit the exact same receptor target. However, cancer cells frequently mutate, hide, or stop expressing targeted proteins, allowing surviving malignant cells to evade standard single-target treatments.
Engineering the Dual-Recognition System
To address tumor evasion, the UCLA team engineered what they term AlloESO-T cells with a dual-recognition system. The first system utilizes the engineered TCR to detect NY-ESO-1, while the second system incorporates natural killer (NK) cell receptors designed to identify stress signals commonly displayed by cancer cells. According to study authors, if a tumor loses or conceals the NY-ESO-1 antigen, the engineered T cells retain a secondary pathway to detect and destroy the malignant tissue.
Preclinical Success in Ovarian Cancer Models
In preclinical testing involving ovarian cancer mouse models, a single injection of AlloESO-T cells produced prolonged tumor suppression and extended survival rates. Researchers observed that the infused cells multiplied approximately 100-fold inside the subjects, migrating directly to tumors and remaining active for weeks while largely avoiding healthy organ accumulation.
Safety Evaluations and Future Trials
Despite the positive preclinical outcomes, the technology remains in the early research phase. Investigators must complete comprehensive safety evaluations to determine whether these allogeneic cells can be effectively controlled within complex human biological environments without triggering adverse immune reactions. Clinical trials will be required before the therapy can be considered for human patients.
>
Related reading
- UCLA Scientists Engineer Cord Blood T Cells to Target Hidden Solid Tumors
- Flu and COVID-19 Twindemic Ahead of Chuseok: Prevention Tips for High-Risk Groups
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)